Sitagliptin in Renal Transplant Recipients

Status Completed

Clinical Trial Summary

The major cause of premature death in renal transplant recipients is cardiovascular disease. Sitagliptin stimulates insulin secretion and inhibits glucagon release, two central mechanisms in PTDM by interaction with a hormone system (incretins) that just recently it has become possible to modulate by drugs. Sitagliptin therefore is an interesting additional drug for the treatment of posttransplant diabetes mellitus in transplanted patients.

The primary objective of the present study is to investigate the effect of sitagliptin on insulin secretion in renal transplant recipients.

Secondary objectives are to study the effect on insulin sensitivity, fasting blood glucose, endothelial function, CsA/Tac blood concentrations.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Glucose Intolerance

Clinical Trial Details

NCT number	NCT00740363
Study type	Interventional
Source	University of Oslo School of Pharmacy
Contact
Status	Completed
Phase	Phase 4
Start date	September 2008
Completion date	June 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05544266` - Rare and Atypical Diabetes Network
Completed	`NCT03241121` - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome	N/A
Completed	`NCT03809182` - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.	Phase 4
Completed	`NCT03675360` - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial	N/A
Completed	`NCT01671293` - Multicomponent Telecare Model for Supporting Prediabetes Patients	N/A
Not yet recruiting	`NCT01402362` - Prevalence of Glucose Intolerance and Risk Factors in Ethiopian Immigrants in Israel; Follow-up Study.	N/A
Completed	`NCT00436475` - Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes	Phase 1/Phase 2
Completed	`NCT04090788` - The Effect of Momordica Charantia Supplementation on Blood Glucose Levels	N/A
Active, not recruiting	`NCT05460884` - Effects of Seaweed Extract on Postprandial Response to White Bread	N/A
Completed	`NCT03348020` - Iron and Insulin Resistance in Overweight and Obese Humans	N/A
Terminated	`NCT03356873` - Impact of Correction of Vitamin D Deficiency in Oxidative Stress in Patients With Prediabetes (VICOX)	N/A
Completed	`NCT03922685` - Effects of Diet and Exercise on Circadian Glycemia	N/A
Completed	`NCT03730727` - Exercise-meal Timing and Postprandial Glucose Control	N/A
Completed	`NCT04743960` - Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition	N/A
Completed	`NCT04004273` - Diabetes, Exercise and Liver Fat (DELIVER)	N/A
Terminated	`NCT01887691` - Sleep Effectiveness and Insulin and Glucose Homeostasis	Phase 1
Completed	`NCT02412995` - The Effects of Sea Buckthorn and Strawberry on Postprandial Glycaemia, Insulinemia and Appetite	Phase 0
Not yet recruiting	`NCT01436448` - Probiotics (Lactobacillus Rhamnosus) in Reducing Glucose Intolerance During and After Pregnancy	Phase 3
Completed	`NCT00862589` - Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)	N/A
Completed	`NCT00006162` - Lifestyle Interventions to Reduce Diabetes Risk	N/A